Publication Date:
2019
Description:
Abstract
The safety of newer xanthine oxidase inhibitor‐febuxostat comparing to allopurinol remains unclear. To compare the risks of allopurinol‐ and febuxostat‐hypersensitivity and cardiovascular diseases (CVD) in Asians, we conducted a population‐based cohort study enrolling patients receiving allopurinol or febuxostat from Chang Gung Memorial Hospital Health System across Taiwan during 2012‐2016 and further performed a meta‐analysis incorporating two recent studies. Among the 61,539 users, a corresponding 12,007 and 5,680 patients were identified as new users. The overall incidence of febuxostat‐hypersensitivity was significantly lower than allopurinol‐hypersensitivity (0.2v.s.2.7 per 1000 new users, P〈0.001). There were 33 allopurinol‐hypersensitivity (including 18 severe cutaneous adverse drug reactions) and only one patient developed febuxostat‐maculopapular exanthema. Moreover, febuxostat was not statistically increased risk of CVD (HR,1.16; P=0.152) and related death (HR,1.49; P=0.496) compared to allopurinol. The result of meta‐analysis also showed consistent result. In conclusion, the incidence and severity of febuxostat‐hypersensitivity are lower than with allopurinol. Febuxostat didn't show an increased risk of CVD and related death.
This article is protected by copyright. All rights reserved.
Print ISSN:
0009-9236
Electronic ISSN:
1532-6535
Topics:
Chemistry and Pharmacology
,
Medicine
Permalink